N@N

GERON CORPORATION (NASDAQ:GERN), Down By 11.38% ($0.19) From $1.670 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2012-05-09 07:40:34 - WOPRAI}
 

May 9, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, May 1st 2012 stating that GERON CORPORATION (NASDAQ:GERN) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=gern&id=269923

At the time this story was written, GERON CORPORATION (NASDAQ:GERN) is Down By 11.38% ($0.19) From $1.670 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

GERON CORPORATION (NASDAQ:GERN) - Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. It develops a range of anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines; and diagnostics based on telomerase detection, as well as intends to develop products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. The company develops Imetelstat (GRN163L), which is in Phase I clinical trial for the treatment of chronic lymphoproliferative diseases, solid tumors, multiple myeloma, and non-small cell lung cancer. GRN163L is also in Phase I/II clinical trial to treat breast cancer. The company also develops GRNVAC1 that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. It also develops GRNOPC1, which is in Phase I Trial for treatment of spinal cord injury; and GRNCM1 that is in preclinical stage to treat heart disease and screening. The company has licensing agreement with Merck & Co. to develop telomerase cancer vaccine, which is in Phase I clinical trial for the treatment of prostate and solid tumors; Sienna Cancer Diagnostics to develop a preclinical stage product for the treatment of bladder cancer; and has a collaboration with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. GERON CORPORATION (NASDAQ:GERN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net